Obicetrapib
Phase 3Small molecule
Obicetrapib is one of 157 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.
6
Indications
18
Total Trials
7
Active Trials
156
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
147 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Primacor
SanofiApproved
Cardene
Sun Pharmaceutical Industries, Inc.Approved
Geodon
PfizerApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Midamor
PPadagis LLC
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Approved
Camzyos
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Colcrys
Jazz PharmaceuticalsPhase 3
Pelacarsen
NovartisPhase 3
Cagrilintide
Novo NordiskPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Randomized3 trials
Imaging1 trial
Lip1 trial
11 more indications
Statin1 trial
Moderate Hepatic Impairment1 trial
Oral1 trial
ART1 trial
Drug Interactions1 trial
Cardiovascular Disease1 trial
Early Alzheimer's Disease1 trial
Lipidemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Obicetrapib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNewAmsterdam Pharma